Nerbacadol is significantly positively correlated with high expression of HOXB-AS4 and drug resistance in head and neck squamous cell carcinoma. Nerbacadol can be used in relevant research on head and neck squamous cell carcinoma [1].
References:
[1]. Lv S, et al. LncRNA HOXB-AS4 Promotes Tumor Malignant Phenotype in Head and Neck Squamous Cell Carcinoma and Serves as a Prognosis Marker. J Cancer. 2025;16(9):2997-3014. Published 2025 Jul 1.
References:
[1]. Lv S, et al. LncRNA HOXB-AS4 Promotes Tumor Malignant Phenotype in Head and Neck Squamous Cell Carcinoma and Serves as a Prognosis Marker. J Cancer. 2025;16(9):2997-3014. Published 2025 Jul 1.
















